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Osteoarthritis (OA) accounts for the majority of the disease burden for musculoskeletal disorders and is
one of the leading causes of disability worldwide. This disability is the result not of the cartilage loss that
deﬁnes OA radiographically, but of the chronic pain whose presence deﬁnes symptomatic OA. It is
becoming clear that many genes, each with a small effect size, contribute to the risk of developing OA.
However, the genetics of OA pain are only just starting to be explored. This review will describe the ﬁrst
genes to have been identiﬁed in genomic studies of OA pain, as well as the possible dual roles of genes
previously identiﬁed in genomic studies of OA in the context of pain. Difﬁculties associated with
attempting to characterise the genetics of OA pain will be discussed and promising future avenues of
research into genetic and epigenetic factors affecting OA pain described.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Recent years have seen substantial advances in the under-
standing of the genetic architecture of osteoarthritis (OA). Unbiased
genetic screens of large OA cohorts such as those included in the
arcOGEN and TREAT-OA consortia have had sufﬁcient power to
reveal a wide range of relatively common susceptibility loci1. These
studies have deﬁned OA according to a composite deﬁnition, with
cases either having structural damage to the joint, evaluated using
radiographic criteria such as the Kellgren Lawrence score, or having
previously undergone joint replacement.
However, the presence of radiographic evidence of OA does not
always correlate with the main clinical presentation of OA, which is
joint pain. Patients consistently describe the most distressing
aspect of living with OA as the fatigue, disability and reduced
quality of life produced by chronic joint pain2. A disease-modifying
drug that restored cartilage without any reduction in pain would
have little clinical utility3. Currently available analgesics have
limited efﬁcacy, high numbers needed to treat and high incidences
of adverse events when taken chronically to combat joint pain4.
Therefore, a greater focus on symptoms as well as aetiology of
cartilage loss is critical if OA research is to produce clinicallyM. Thakur, Neurorestoration
, Kings College London Guy’s
, matthew.thakur@kcl.ac.uk
s Research Society International. Prelevant therapies. Some recent genomic studies have acknowl-
edged this by including a large proportion of patients who had
previously undergone joint replacement1. Joint pain is likely to be
the main factor prompting the decision to replace joints in these
patients. But despite this fact, there have been very few studies
which set out to speciﬁcally examine the genomic factors under-
pinning OA pain, in contrast to the relatively well characterised
genomics of broadly-deﬁned OA risk and cartilage loss.
This review will describe the genes identiﬁed in current OA
genomic studies which focussed on joint pain, as well as the
possible dual roles of genes identiﬁed in broader genomic studies of
the disease. The difﬁculties and limitations of genetic and epige-
netic studies will also be discussed.
Which genes are currently known to associate with OA pain?
The gold standard for genetic association studies are unbiased
Genome-Wide Association Studies (GWAS). These are well suited to
the identiﬁcation of common gene variants with small or large
effects, but require large cohorts of patients to provide sufﬁcient
statistical power, and hence are costly to perform. An example is
the £2.2 million arcOGEN study, which in its ﬁrst phase compared
7410 patients with severe OAwith 11,009 unrelated controls in a UK
cohort, and went on to replicate the most promising signals from
this cohort in a wider European cohort of 7473 cases and 42,923
controls1.
Although 80% of patients included had undergone joint
replacement, the arcOGEN study did not set out to identify genetic
inﬂuences on pain in OA per se, but used a focus on severe OA as aublished by Elsevier Ltd. All rights reserved.
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homogeneity of their OA cohort. As the decision to perform joint
replacement in these patients would have been informed princi-
pally by the degree of pain and disability the patients were expe-
riencing, the presence of joint replacement can arguably function
as a valid proxy for explicit measures of joint pain.
As part of its analysis, the study did look for loci that had
stronger association in a joint replacement only subset of patients
(i.e., those who had experienced pain associated with OA) vs the
broader composite-deﬁned cohort (which included the patients
who only had radiographic changes). Four such loci were found,
corresponding to chromosome regions close to the genes GLT8D1,
ASTN2, CHST11 and TP63, none of which are presently represented
in the pain literature. Investigations of the role of these genes in
preclinical models of OA painwill reveal if they can be manipulated
to affect pain outcomes.
A study guided by a novel imputation strategy in the arcOGEN
cohort genotyped an single nucleotide polymorphism (SNP) in
MCF2L as a risk locus for OA5. MCF2L codes for the Rho-speciﬁc
Guanine nucleotide exchange factor DBS. DBS is phosphorylated
by TrkC, a receptor of the Nerve Growth Factor (NGF)-family
member neurotrophin NT-3, and enhances Schwann cell migration
when activated6. Growth factors are potent regulators of pain-
sensing ﬁbre function7. Antibody therapies neutralising NGF are
the single most promising putative analgesics currently being
assessed for OA pain8.MCF2L regulation of Schwann celleneuronal
interaction could conceivably play a role in the dysregulated
articular innervation observed in osteoarthritic cartilage9. Howev-
er, NT-3 is expressed at very low levels in synovial ﬂuid of in-
dividuals with RA and OA compared to expression of the other
neurotrophic factors NGF and brain derived neurotrophic factor
(BDNF)10. Also, the SNP was equally frequently found in the
radiographically- and symptomatically-deﬁned cohorts used in the
study. This makes it less likely that this SNP has a speciﬁc role in OA
pain over cartilage loss.
To date, the only adequately powered GWAS to be carried out in
the pain ﬁeld was for chronic widespread pain11. This may reﬂect
the difﬁculties in undertaking time-consuming and potentially
expensive standardised quantitative phenotyping of this subjective
phenomenon across a large cohort of individuals of diverse ethnic
and cultural backgrounds. Accordingly, candidate gene association
studies, which can be adequately powered with much smaller co-
horts, are more common in the pain ﬁeld. However, as these
smaller studies are hypothesis-led, they tend to have a narrow
focus on genes already known to be involved with pain sensitivity,
and are thus more likely to produce false positive results.
One reason for the relatively small body of detailed data on pain
genomics in OA is that the cohorts used for radiographic OA GWAS
tend to be community-based, while symptomatic criteria tend to be
better reported and assessed in clinical settings. Additionally,
radiographic reporting criteria are more standardised than symp-
tomatic reporting criteria, which frustrates the formation of large
subgroups of patients with similar symptomatic proﬁles12. How-
ever, from the existing studies, there are ﬁve genes claimed to
associate with OA pain.
The SCN9A gene encodes the alpha subunit of voltage gated so-
dium channel Nav1.7. This is selectively expressed by nociceptors
and known to be essential for transmission of pain-related signals.
Rare mutations in the channel confer a congenital insensitivity to
pain. In contrast, gain of function is seen inprimaryerythromelalgia,
ﬁbromyalgia and idiopathic small ﬁbre neuropathy13e15. These
mutations have Mendellian characteristics. In addition, however, a
SNP conferring an Arg-1150-Trp substitution in this channel was
found to associate with higher pain reports in four clinical trial co-
horts of 578 OA patients, as well as in a variety of other painfulconditions and healthy controls. The SNP in question is present in
10% of people and was thought to account for around 0.8 points on
the 20 point Western Ontario and McMaster Universities Arthritis
Index (WOMAC) pain subscale16. Unfortunately this SNP has failed
to replicate in a larger independent cohort17. The authors of
the latter study conclude that their result may be consistent with a
weak effect of the Arg-1550-Trp substitution on overall pain sensi-
tivity, rather than a speciﬁc effect in OA, as the SNPwas also present
more often in individuals with poorly localised multiple regional
pains.
TRPV1 is a ligand-gated ion channel enriched on thermosensi-
tive peripheral nerve ﬁbres. TRPV1 is expressed on articular
chondrocytes18, as well as intraarticular nerve ﬁbre terminals19,20.
Ile-585-val TRPV1 variants are reported to confer reduced sensi-
tivity to cold pain21,22. The IleeIle variant is associated with lower
risk of symptomatic vs asymptomatic knee OA (odds ratio
(OR) ¼ 0.74) in a cohort of 3270 symptomatic vs 1098 asymptom-
atic cases23. This association was speciﬁc to symptomatic OA, and
was not seen in patients with radiographic changes but no pain.
There are many other SNPs in TRPV1 which are already known to
affect pain reporting24. It will be interesting to assess whether these
other variations also have any association with symptomatic OA
over asymptomatic OA.
Paired amino acid converting enzyme 4 (PACE4, coded by the
Pcsk6 gene) is an enzyme in cartilage that activates the cartilage
degrading aggrecanases ADAMTS-4 and -525. In a candidate gene
study in 674 patients with radiographic knee OA with pain vs 2068
radiographic knee OA/no-pain patients, a SNP in Pcsk6was strongly
associated with protection against pain when radiographic OA was
present, with an OR of 1.33. While there was no further investiga-
tion to determine whether this speciﬁc SNP conferred a loss or gain
of function, the group also performed a number of pain tests in
Pcsk6 null transgenic mice. These mice had, on the whole, a normal
pain phenotype, with the exception of a mild reduction in me-
chanical sensitivity as well as substance P- and acetic acid-evoked
pain behaviours26. Unfortunately, the phenotype of these mice in
experimental OA models is not yet known.
P2X7 is a purinergic channel expressed on cells of myeloid
lineage such as macrophages. A SNP in this gene determines the
ability of the channel to form a pore that allows high molecular
weight material to pass through the membrane. P2X7 is highly
polymorphic in humans27. Individuals with radiographic OA
(numbering 743 cases) possessing the hypofunctional variant of the
channel were signiﬁcantly less likely to have clinically relevant OA
pain when compared with 586 unaffected controls (deﬁned quite
liberally at a WOMAC score >3 in this study e 6 is more often used
as the cutoff). This study also showed that SNPs in P2X7 associated
with pain intensity in a post-masectomy pain cohort. P2X7-
selective antagonists are currently being evaluated as analgesics
in both inﬂammatory and neuropathic pain states28, though there
are currently no studies of the role of this gene in experimental OA.
Finally, the common Val-158-Met polymorphism reduces the
activity of the catecholamine degrading enzyme catechol-O-
methyltransferase (COMT). This SNP was shown to increase the
risk of hip pain amongst 171 female, but not 288 male individuals
with conﬁrmed radiographic OA, with an OR of 4.929. COMT poly-
morphism is also known to associate with maladaptive coping and
pain catastrophising in ﬁbromyalgia and shoulder pain30,31, aswell as
inﬂuencing acute experimental pain reports in healthy controls32.
When assessing these studies, it is important to note the rela-
tively small cohorts used. With one of the genes linked to OA pain
already shown not to replicate in a larger cohort, it remains to be
seenwhether the contribution of the other genes will be conﬁrmed
or refuted by further studies. The genes linked to pain in OA are
summarised in Table I.
Table I
Genes identiﬁed by genomic studies of symptomatic OA
Gene Protein Effect in OA Study size Reference
Glt8d1 Glycosyltransferase 8
domain-containing 1
More often found in cases deﬁned
purely by presence of joint replacement
vs cases deﬁned using composite
measure of radiographic change
and/or replacement
7410 hip and/or knee OA cases vs
11,009 controls. Approx. 80% of
cases had undergone joint
replacement.
1
Astn2 Astrotactin 1
Chst11 Chondroitin
sulfotransferase 11
Tp63 Tumour protein P63
Mcsf2L Rho-speciﬁc Guanine
nucleotide exchange
factor DBS, phosphorylated
by TrkC
SNP enriched in cases vs controls e
but common in both radiographic
and symptomatically-deﬁned cohorts
19,041 cases vs 24,504 controls in
meta-analysis. Approx. 80% of cases
had undergone joint replacement.
5
Scn9A Voltage gated Sodium
Channel 1.7 (Nav1.7)
expressed in peripheral nerve
Arg-1150-Trp substitution associated
with higher pain reports; failed to
replicate.
578 patients with symptomatic OA
in original study (radiographic
status omitted), 1325 ROA þ Pain
or TKA vs 529 ROA only in replication
(KL variable)
16,17
Trpv1 Transient receptor potential
cation channel, subfamily V,
member 1 (TRPV1), peripheral
nerve nociceptor channel
Il-585-Val SNP associates with a
25% lower risk of symptomatic OA
3270 ROA þ pain vs 1098 ROA only
cases (KL  3 or TKA)
23
Pcsk6 PACE4, activates aggrecanases SNP enriched in asymptomatic patients
with radiographic OA
2068 ROA þ pain vs 674 ROA only
(KL  2)
26
P2x7 P2X purinoceptor 7, ligand-gated
ion channel allowing formation
of large pores on dendritic cell
membranes
Hypofunctional SNPs associate with
less severe pain
743 Symptomatic OA vs 586 controls
(radiographic status omitted)
33
Comt COMT, catecholamine degrading
enzyme
Hypofunctional Val-158-Met polymorphism
confers 30% increased risk of pain in females
but not males with radiographic OA
105 ROA þ pain vs 171 ROA only
(KL  2)
29
ROA ¼ osteoarthritis deﬁned on radiographic criteria alone.
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In addition to the identiﬁcation of genes which associate with
OA pain in genetic variation studies, changes in gene function can
also be assessed using expression proﬁling. One study used
expression proﬁling of blood leukocytes to identify a subgroup of
symptomatic OA patients who overexpressed IL-1B, reported
higher pain scores, and were at greater risk of radiographic pro-
gression34. However, very few of the existing expression proﬁles of
osteoarthritic tissue were originally designed with pain genes in
mind, and many focus exclusively on chondrocytes or matrix
proteins.
The exception is a study which compared gene expression in
cartilage of OA patients and healthy controls using genome-wide
microarray analysis35. Table II presents the genes with greater
than 10 fold positive or negative change in expression with a
known role in pain (based on available publications on Pubmed).
These amount to 35% of the total genes with >10 fold change (22/
63). Many of these genes encode proteins that can activate noci-
ceptors. In preclinical pain research, intraarticular monosodium
iodoacetate (MIA) has been widely used to model OA-like joint
pain. This leads to histopathological changes in rodents which have
some of the features seen in osteoarthritic human cartilage, and is
accompanied by robust and well deﬁned alterations in pain-related
behaviours36. Microarray analysis of cartilage from the MIA model
found that nearly 2000 genes were signiﬁcantly dysregulated, with
many of these genes related to degradation and inﬂammatory
processes37. However when compared to human OA cartilage, less
than 4% of the differentially expressed genes were common with
the rat. The reason for such a large discrepancy in gene expressionis unclear but may reﬂect the different etiologies of the experi-
mental model and the naturally-occurring disease.
In contrast, a recent study showed that gene expression in
humans and rats is highly signiﬁcantly correlated in a translational
model of experimental inﬂammatory pain38. These studies together
suggest that, while there is little similarity in the underlying
mechanisms governing the tissue degeneration process in pre-
clinical models of OA vs clinical disease states, the pathogenesis of
pain may involve substantial commonalities.
Do any of the genes identiﬁed in genomic studies of cartilage
loss in OA have known roles in pain?
A frequently cited aspect of OA is the discordance said to exist
between radiographic changes in the joint and symptoms of joint
pain or stiffness69. However, a number of recent studies have pre-
sented evidence for a greater degree of concordance between
structural and symptomatic events in OA than had previously been
acknowledged. This may reﬂect the increased use of higher reso-
lution magnetic resonance imaging of joint tissue70e72 as well as
greater standardisation in the reporting of radiographic ﬁndings12.
However, it remains true at the population level that there are
many patients with severe radiographic changes who are asymp-
tomatic, as well as individuals experiencing joint pain with only
minimal radiographic changes. One longitudinal study found that
only 56% of patients with a Kellgren Lawrence grade (KL) 3 were
currently experiencing joint pain73.
These caveats may account for the fact that very few of the
existing genes linked to cartilage loss in genomic studies, such as
DOT1L, have any known role in the regulation of pain74. However,
Table II
Genes identiﬁed through expression proﬁling in osteoarthritic cartilage with >10 fold change þ or , annotated with known pain role, grouped according to biological role.
Genes with no pain role not shown. OA microarray data from35
Upregulated Gene Protein name Role in pain
Cytokines LIF Leukemia inhibitory factor Anti-inﬂammatory and analgesic39, but can also induce
mechanical hyperalgesia40
Chemokines IL8 Interleukin 8 Hyperalgesia-inducing via sympathetic nervous system41,42.
Anti-CXCL8 serum reduces inﬂammatory pain41
CXCL2 Chemokine (CeXeC motif) ligand 2 No effect on pain sensing43
CCL2 Chemokine (CeC motif) ligand 3 Pronociceptive when upregulated in spinal cord44,45.
Induce hyperalgesia when given peripherally46e48. KO
of receptor prevents nerve-injury induced mechanical hyperalgesia46.
CXCL14 Chemokine (CeXeC motif) ligand 14 Upregulated in inﬂammatory pain49
CCL3 Chemokine (CeC motif) ligand 2 Proinﬂammatory, sensitises TRPV150. Induces hyperalgesia
when administered locally50,51
Enzymes MMP13 Matrix metallopeptidase 13
(collagenase 3)
Regulated by miRNA-146a in OA pain52
PDE4B Phosphodiesterase 4B Null mice have normal pain53
JMJD3 Jumonji domain containing 3 Can alter histone methylation in response to inﬂammation54
Growth Factors IGF1 Insulin-like growth factor 1 Underexpressed in ﬁbromyalgia55
Matrix Components TNC Tenascin C Interacts with voltage gated sodium channel subunit beta56
Bone-related POSTN Periostin, osteoblast speciﬁc factor Downregulated by NSAID rofecoxib57
Others RGS1 Regulator of G-protein signaling 1 Tonically antagonises opioid receptors58
AQP1 Aquaporin 1 Coexpressed in Nav1.8 positive C ﬁbres, but KO has no change
in pain phenotype59
PENK Proenkephalin Released by peripheral immune cells. KO increases pain behaviours60
MARCKS Myristoylated alanine-rich protein
kinase C substrate
Phosphorylation of spinal MARCKS maintains neuropathic pain61
ASPN Asporin Associated with lumbar disc degeneration pain62
WNT5A Wingless-type MMTV integration
site family 5A
Abberant activation association with acute, chronic and
inﬂammatory pain63e65.
SFRP4 Secreted frizzled-related protein 4 Differentially regulated after nerve injury in mice with
disrupted nociception66
Down regulated Gene
FKBP5 FK506 binding protein 5 Variants predict neck pain persistence after injury67
TXNIP Thioredoxin interacting protein Regulates diabetic neuropathy68
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terised pain phenotypes or close links to pain targets.
The ﬁrst is TRPV4. A loss of function mutation in TRPV4 was
shown to be associated with inherited osteoarthropathy, suggest-
ing a role for TRPV4 in articular cartilage homeostasis75. TRPV4 is
known to have functions in visceral pain, transduces hypotonicity-
evoked pain and is a target for a number of pro-algesic inﬂamma-
tory mediators including prostaglandin E276e78. However, it is
currently not clear whether TRPV4 is expressed on articular
nociceptors.
The second gene identiﬁed from studies of OA deﬁned radio-
graphically is the interleukin-1 receptor. A candidate gene study
and a large meta-analysis identiﬁed an association between the
C-T-A haplotype of IL1RN, the IL-1 receptor antagonist, and reducedseverity of radiographic OA79,80. IL1R knockout mice have a reduced
pain phenotype81, and cytokines play a key role in the generation
and maintenance of joint pain82. Unfortunately, the frequency and
severity of the symptomatic OA phenotype in the populations from
these studies is not reported, and the meta-analysis indicates that
the effect of the IL1RN polymorphism on OA risk is likely to be
weak79,83.
In the ﬁeld of rheumatoid arthritis, there are now a number of
studies suggesting that the temporal relationship between pharma-
cological analgesia and disease course may differ, with onset of pain
relief apparently preceding changes in joint disease in some in-
stances84e86. Thepotential dual roleof thegenesdiscussedabovebegs
the question of whether these factors could directly alter pain trans-
mission, aside from any known effects on articular pathology in OA.
M. Thakur et al. / Osteoarthritis and Cartilage 21 (2013) 1374e13821378The limitations of genomic studies of painful joint disorders
One potential confounding factor of the studies described above
is the ﬁnding that the presence of knee pain can affect X-ray im-
aging of the joint in extension. This effect will occur when imaging
the weight-bearing anterioposterior aspect, due to the disinclina-
tion of patients experiencing greater knee pain to fully extend the
affected joint87. Thus changes in joint space narrowing in clinical
trials and epidemiological studies of radiographic OA progression
may not be entirely independent of (often unexamined) variation
in the symptomatic status of the population being studied79,83.
Another potential confounding factor is ethnic variation in pain
sensitivity. Ethnic variation in genes associated with cartilage loss
in OA has been repeatedly encountered, frustrating efforts to
replicate promising GWAS candidates88. It is already clear that
signiﬁcant differences in pain perception exist in individuals from
different ethnic backgrounds89. Any large-scale studies of symp-
tomatic OA will have to take this into account.
The likely factors with the strongest inﬂuence on persistent pain
in OA are illustrated by the study of OA patients with poorly
controlled symptomatic OA who undergo total knee arthroplasty
(TKA). Patients who will go on to require TKA are distinguished by
reduced joint ﬂexion, effusion and pain; interestingly, even severe
radiographic degeneration has no bearing on the need for joint
replacement90. Joint replacement signiﬁcantly reduces knee pain
reports in the majority of cases. However, it is also true that up to
44% of patients experience some degree of persistent pain 3e4
years after surgery. Patients’ description of their pain indicates that,
in most cases, this persistent pain is not simply due to intra-
operative nerve damage. The strongest risk factors for pain per-
sisting after knee replacement were the existence of coincident
pain at other sites, and comorbidity of major depression91. This
suggests that genes found to associate with OA pain in studies
which do not correct for the presence of comorbid pain and
depression in their OA cohorts may in fact be genes associated with
these risk factors. For example, polymorphism in COMT is known to
have a role in mood disorders, as well as symptomatic hip
OA29,92,93.
Genomic studies of painful conditions similar in pathogenesis
to OA are likely to also be relevant to OA pain. The OPPERA study
of temporomandibular disorder (TMD, a chronic joint pain dis-
order with a large affective component) is one example. Similarly
to individuals with symptomatic OA, individuals with TMD in the
OPPERA study are more sensitive to pain applied elsewhere on
the body and experience greater temporal summation of noxious
stimuli, indicating central sensitization94,95. TMD sufferers were
also more likely to have suffered previous trauma, and had more
comorbid pain conditions, like OA patients with persistent
pain91,96. The two most promising SNPs identiﬁed in the analysis
of the OPPERA cohort are SNPs in COMT, as described above, and
the serotonin receptor HTR2A97. Revealingly, SNPs in HTR2A are
also associated with the risk of chronic widespread pain98.
The identiﬁcation of genes regulating general pain sensitivity,
as opposed to speciﬁc OA pain risk, concurs with data from twin
studies and studies of COMT polymorphism. Taken together,
these diverse studies indicate strong underlying genetic factors
for general pain reporting across many body sites, as opposed to
factors regulating pain reporting at speciﬁc sites or in speciﬁc
conditions32,99. COMT polymorphism may also determine
magnitude of response to both analgesics and placebos100e102.
This implies that genomic data may be of great utility in the
design of enriched-enrolment clinical trials for symptomatic OA
treatments, to maximise the differentiation of drug-treated and
placebo-treated groups. But genomic data may be less successful
in providing a means of tailoring treatments for individuals,other than ﬂagging patients who are likely to require greater
analgesia.
Promising future avenues of research into genetic and
epigenetic factors affecting symptomatic OA
Endophenotypes in symptomatic OA
One way of increasing the power of genetic studies hoping to
identify quantitative trait loci is to focus on endophenotypes, rather
than the simple case status (in this case, the latter would be the
presence or absence of radiographic/symptomatic OA). Endophe-
notypes are measurable intermediate biomarkers that may have a
more direct relationship to a gene product103. An example in OA is a
GWAS that identiﬁed genes linked to cartilage thickness, as deﬁned
by degree of joint space narrowing74.
In symptomatic OA, a focus on endophenotypes could entail
subdivisions such as: low, medium and high pain intensity groups;
patients whose pain persists following total knee replacement and
patients whose pain is resolved; patients who experience pain
localized to the joint alone and thosewho experience referred pain;
patients who experience pain with neuropathic features and those
without any neuropathic component; patients whose pain is well
controlled by non-steroidal anti-inﬂammatory drugs (NSAIDs) and
those with uncontrolled pain.
A handful of studies in the pain ﬁeld are already using these
stratiﬁed populations on a smaller scale to probe the neurobiology
of symptomatic OA in patients and in preclinical models91,104e106.
Deployed on a larger scale, such studies could use endophenotypes
to deliver more powerful and clinically relevant genomic data on
the extremely heterogeneous symptomatic OA population. Endo-
phenotype analysis is already being attempted in the OPPERA TMD
cohort, and has identiﬁed potentially distinctive clusters of gene
regulation in patients who experience localized vs more wide-
spread pain92.
Epigenetics
Epigenetics is the study of mechanisms that regulate gene
function, which can be heritable or stabilised within an individual,
without altering the DNA sequence. Examples of such include
histone modiﬁcation and DNA methylation. So far genetic variation
studies have identiﬁed a number of relatively common candidate
genes with small effects on overall risk of OA, deﬁned radio-
graphically. However these genes cannot fully explain the strong
genetic component which is evident in OA107. Therefore other
mechanisms must be involved e such as epigenetics.
Existing epigenetic studies have focussed on articular cartilage,
where DNAmethylation and histone modiﬁcation have been linked
to the production of catabolic factors which regulate cartilage
degradation108. Recently, epigenetic mechanisms have also been
implicated in the development andmaintenance of chronic pain109.
For instance, the direct manipulation of histone modiﬁcation
mechanisms through the use of histone-deacetylase inhibitors can
reduce pain-related behaviours in animals subjected to an inﬂam-
matory insult110. It is therefore conceivable that epigenetic modi-
ﬁcations contribute to OA pain. One possible avenue might be via
the regulation of the immune systemwhich has well characterised
epigenetic components111. Immune cells are active players in OA
pathology and can produce pro-algesic factors such as cytokines
and chemokines, which likely contribute to OA pain. The produc-
tion of such factors is thought to be strongly inﬂuenced by epige-
netic processes112,113.
Micro (mi)RNAs are another way in which gene function can
be regulated without changing the DNA sequence. RNA
M. Thakur et al. / Osteoarthritis and Cartilage 21 (2013) 1374e1382 1379interference regulates gene expression through the production of
small RNA sequences (miRNAs) which can bind to target mRNAs
and prevent translation. Genetic deletion of Dicer, an important
enzyme in miRNA production, shows that this process is impor-
tant for the ability to detect inﬂammatory pain114. In OA, miRNAs
play a role in disease progression, in particular by regulating
chondrocyte function, and may contribute to cartilage degrada-
tion115. miRNA-146a has been linked to OA progression since its
expression is upregulated in OA cartilage116. In rats this miRNA
can regulate the expression of many inﬂammatory genes which
may contribute not only to chondrocyte dysfunction but also
pain117. In human chondrocytes miRNA-199 has been shown to
directly regulate the expression of COX-2, the rate-limiting
enzyme in prostaglandin synthesis118. Since COX-2 is the target
of NSAIDs, the ﬁrst line analgesic treatment used in OA patients, it
seems possible that miRNA-199 might directly inﬂuence pain
sensitivity in OA through the regulation of pain mediator pro-
duction, in this case prostaglandin.
Conclusion
Recent years have seen an explosion in the volume and quality
of genomic studies in the ﬁeld of OA. A minority have set out to
identify genes that regulate joint pain in OA. In future studies of the
genetic architecture of OA pain, the use of endophenotypes and a
focus on epigenetic processes will help to clarify the role of genetic
and epigenetic factors in the development of OA pain. The subse-
quent advances in understanding should contribute greatly to the
design of effective treatments which could relieve the substantial
burden of OA pain.
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